Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting ...

This maker of weight-loss drugs saw its share price zoom and then crash. The CEO has been replaced. The incoming boss will ...

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower ...

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...

Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.

A string of blunders led to the value of Novo Nordisk dropping £52bn last week. Could a new weight-loss pill help it regain ...